NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$26.11

+0.66 (+2.59 %)

(As of 04/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$25.18

Now: $26.11▼

$26.28

50-Day Range

$25.45

MA: $31.60▼

$37.12

52-Week Range

$24.77

Now: $26.11▼

$55.22

Volume166,904 shs

Average Volume295,390 shs

Market Capitalization$1.14 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.36

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:YMAB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ymabs.com

Phone646-885-8505

Employees125

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio10.40

Quick Ratio10.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.01 per share

Price / Book5.21

Profitability

EPS (Most Recent Fiscal Year)($2.30)

Net Income$-81,030,000.00

Net MarginsN/A

Return on Equity-74.98%

Return on Assets-66.70%

Miscellaneous

Outstanding Shares43,526,000

Market Cap$1.14 billion

Next Earnings Date5/6/2021 (Estimated)

OptionableNot Optionable

Headlines

Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer
April 20, 2021 | finance.yahoo.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 2.9%
April 20, 2021 | americanbankingnews.com

BRIEF-Y-Mabs Therapeutics- Concluded A Type B Meeting With Fdaregarding Omburtamab
April 20, 2021 | msn.com

Y-mAbs Provides Regulatory Update on Omburtamab
April 20, 2021 | finance.yahoo.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $186,270.00 in Stock
April 14, 2021 | americanbankingnews.com

Y-mAbs Announces GPA33-SADA Data Presented at AACR
April 12, 2021 | finance.yahoo.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 2.7%
April 12, 2021 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Reaches New 1-Year Low at $27.69
April 9, 2021 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Overweight" Rating at JPMorgan Chase & Co.
March 29, 2021 | americanbankingnews.com

Oversold Conditions For Y-mAbs Therapeutics
March 24, 2021 | nasdaq.com

Y-mAbs: Different Data For Different Audiences, Concerning Management History, And Insider Stock Sales - Price Target $16
March 17, 2021 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Are Reducing Their Forecasts For This Year
March 1, 2021 | finance.yahoo.com

Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful?
February 25, 2021 | finance.yahoo.com

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments
February 25, 2021 | finance.yahoo.com

Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 22, 2021 | markets.businessinsider.com

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021
February 19, 2021 | finance.yahoo.com

Y-mAbs Therapeutics (YMAB) Shares Cross Below 200 DMA
February 17, 2021 | nasdaq.com

United Therapeutics launches first product of 2021 after Covid-related delays
February 10, 2021 | bizjournals.com

YMAB Feb 2021 70.000 call
January 17, 2021 | au.finance.yahoo.com

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference
January 6, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.63 out of 5 stars

Medical Sector

359th out of 2,018 stocks

Pharmaceutical Preparations Industry

167th out of 772 stocks

3.4 Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $58.14, Y-mAbs Therapeutics has a forecasted upside of 122.7% from its current price of $26.11.
Amount of Analyst Coverage
Y-mAbs Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Y-mAbs Therapeutics has received 92 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Y-mAbs Therapeutics has received 95 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Y-mAbs Therapeutics has received 50.80% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote “Outperform” if you believe YMAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $443,800.00 in company stock.
Percentage Held by Insiders
38.40% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.20% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($3.25) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -8.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -8.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 5.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$26.11

+0.66 (+2.59 %)

(As of 04/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,620,000 shares, an increase of 27.9% from the March 15th total of 2,830,000 shares. Based on an average trading volume of 306,900 shares, the days-to-cover ratio is currently 11.8 days. Currently, 12.8% of the shares of the stock are sold short.
View Y-mAbs Therapeutics' Short Interest.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Y-mAbs Therapeutics.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings results on Friday, February, 26th. The company reported ($0.48) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.84) by $0.36.
View Y-mAbs Therapeutics' earnings history.

How has Y-mAbs Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, YMAB stock has increased by 13.6% and is now trading at $26.11.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for YMAB?

8 brokers have issued 12 month price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $45.00 to $71.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $58.14 in the next year. This suggests a possible upside of 122.7% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:

Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 51, Pay $766.75k)
Dr. Claus Juan MÃ¸ller San Pedro M.D., Ph.D., CEO & Director (Age 59, Pay $967.5k)
Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 49, Pay $608.35k)
Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 47)
Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 70)
Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 57)
Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 42)
Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

Who are some of Y-mAbs Therapeutics' key competitors?

Some companies that are related to Y-mAbs Therapeutics include Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), I-Mab (IMAB), Arena Pharmaceuticals (ARNA), Hypera (HYPMY), Agios Pharmaceuticals (AGIO), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), Emergent BioSolutions (EBS), Turning Point Therapeutics (TPTX), Atea Pharmaceuticals (AVIR), Nektar Therapeutics (NKTR), Insmed (INSM), ACADIA Pharmaceuticals (ACAD) and PTC Therapeutics (PTCT).
View all of YMAB's competitors.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.00%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $26.11.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $1.14 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 125 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 4/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here